Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lysergic acid diethylamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lysergic acid diethylamide overview
Lysergic acid diethylamide is under development for the treatment of attention deficit hyperactivity disorder (ADHD), anxiety disorders, cluster headaches, acute and chronic pain and psychiatric disorders such as major depression disorder, generalized anxiety disorders. It is a psychedelic drug. It is administered through oral route. The drug candidate acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A).
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a pharmaceutical drug development and clinical research company. The company develops medicinal products to treat brain health disorders, psychiatry, pain and substance use disorders, and related therapeutic areas. Its product offerings include psychedelic and empathogen drugs. The company offers research and development supports such as non-clinical, pre-clinical, human clinical trials and investigator-initiated trials. It also develops drugs support clinical data opportunity in autism spectrum disorders (ASD), address a critical gap in opioid use disorder (OUD) treatment. MindMed is headquartered in New York, the US.
For a complete picture of Lysergic acid diethylamide’s drug-specific PTSR and LoA scores, buy the report here.